Back

Influence of achieved LVEF on efficacy of dapagliflozin in patients with heart failure with improved ejection fraction: the DELIVER trial

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - epidemiology, prognosis, outcome 3 Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Sara Rodrigues De Oliveira Siqueira

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Neutrophil-to-lymphocyte ratio (NLR) and mortality in heart failure: analysis of population-level data
Mr M. Morsy (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Pain and anxiety in heart failure - findings from FINEARTS-HF
Doctor M. Yang (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
Prognostic stratification of acute heart failure patients using the 3C-HF SCORE: short vs long term prediction
Doctor M. Gori (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Health-related quality of life in women versus men with heart failure across the spectrum of LVEF
Doctor M. Yang (Nanjing, CN)
Abstract Slides Video
Presentation thumbnail
Machine learning does not improve risk prediction in heart failure in comparison to the PREDICT-HF model: derivation and validation in PARADIGM-HF and ATMOSPHERE
Doctor A. Talebi (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - epidemiology, prognosis, outcome 3

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
In-hospital course of patients with heart failure with Improved ejection fraction in the DELIVER Trial
thumbnail
Congress Presentation
EVOLUTION-HF DEallEF: a non-interventional study program of patients with heart failure and initiated on dapagliflozin: results of 1st interim analysis
thumbnail
Congress Presentation
Prevalence, prognosis, and factors associated with heart failure with improved ejection fraction: single centre experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources